🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Diffuse Large B-Cell Lymphoma

Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia NCT05281809Phase 21 site📍 Pittsburgh John Lister · Tests: Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous) Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies NCT07284433Phase 1, Phase 213 sites📍 Chicago📍 Evanston📍 Providence AvenCell Therapeutics, Inc. · Tests: Cyclophosphamide (Non-IMP, Lymphodepletion), Fludarabine (Non-IMP, Lymphodepletion), Allo-QuadCAR01-T DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12) NCT07059650Phase 1, Phase 213 sites📍 Beijing📍 Changsha📍 Chengdu Dizal Pharmaceuticals · Tests: DZD8586+R-CHOP, DZD8586+R-GemOx, DZD8586+BR This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma NCT07121946Phase 16 sites📍 Duarte📍 St Louis📍 Buffalo LTZ Therapeutics, Inc. · Tests: LTZ-301, LTZ-301, LTZ-301 A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies NCT05908409Phase 1, Phase 211 sites📍 Santander📍 Salamanca📍 Barcelona IDP Discovery Pharma S.L. · Tests: IDP-121 A First-in-human Study to Assess OT-C001 (Amplified/Activated Allogenic Natural Killer Cells) in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma NCT07044050Phase 11 site📍 Montpellier Emercell SAS · Tests: allogenic natural killer cells Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas NCT06176690Phase 12 sites📍 Houston📍 Houston Baylor College of Medicine · Tests: C7R.CD30.CAR-EBVST cells Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma NCT07763210Phase 21 site📍 Nashville Vanderbilt-Ingram Cancer Center · Tests: Therapeutic Hydrocortisone, Cytarabine, Dexamethasone, Methylprednisolone, Cyclophosphamide Impact of an APA Program on EFS in Patients With Diffuse Large-cell B Lymphoma Treated in 1st Line NCT04670029Phase 35 sites📍 Besançon📍 Le Mans📍 Nancy Weprom · Tests: Adapted physical activity Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) NCT03936153Phase 223 sites📍 Beijing📍 Beijing📍 Beijing Xynomic Pharmaceuticals, Inc. · Tests: abexinostat SynKIR-310 for Relapsed/Refractory B-NHL NCT06544265Phase 15 sites📍 Denver📍 Atlanta📍 Fairway Verismo Therapeutics · Tests: SynKIR-310 Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression NCT06005870Phase 21 site📍 Wuhan Huazhong University of Science and Technology · Tests: Zanubrutinib plus RCHOP Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma NCT06588205n/a20 sites📍 Alessandria📍 Ancona📍 Bari Fondazione Italiana Linfomi - ETS Prospective ctDNA Testing in Large B-Cell Lymphoma NCT07878351n/a2 sites📍 Beijing📍 Beijing Peking University People's Hospital · Tests: Standard-of-care first-line immunochemotherapy containing an anti-CD20 monoclonal antibody and an anthracycline, such a… R-CDOP Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma With High Tumor Burden NCT05040555NA1 site📍 Changchun oubai, MD/PhD · Tests: R-CDOP Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma NCT06015880Phase 18 sites📍 Duarte📍 Sacramento📍 Tampa National Cancer Institute (NCI) · Tests: Biospecimen Collection, Computed Tomography, Lenalidomide, Mosunetuzumab, Polatuzumab Vedotin Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy NCT05757219Phase 21 site📍 Tampa H. Lee Moffitt Cancer Center and Research Institute · Tests: Itacitinib, Chimeric antigen receptor (CAR) T-cell therapy Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL NCT05552937Phase 21 site📍 Hangzhou Beijing InnoCare Pharma Tech Co., Ltd. · Tests: Tafasitamab and Lenalidomide A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL NCT05514327NA1 site📍 Beijing Peking Union Medical College Hospital · Tests: ultra-fraction radiotherapy Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies NCT05887167Phase 11 site📍 Los Angeles Joshua Sasine, MD, PhD · Tests: autologous hematopoietic stem cells added to planned CAR T Long-term Follow up Local Registry Study of Kymriah in South Korea NCT06785818n/a18 sites📍 Bundang Gu📍 Seongnam-si📍 Gyeonggi-do Novartis Pharmaceuticals · Tests: Tisagenlecleucel GVM±R in Patients With Relapsed or Refractory Aggressive NHL. NCT06244368Phase 21 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: GVM±R regimen Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma NCT05077527Phase 17 sites📍 Duarte📍 Chicago📍 New York AIDS Malignancy Consortium · Tests: Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma NCT06765317Phase 28 sites📍 Basking Ridge📍 Hackensack📍 Middletown Memorial Sloan Kettering Cancer Center · Tests: Glofitamab, Polatuzumab, Rituximab, Cyclophosphamide, Doxorubicin A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma NCT05800366Phase 23 sites📍 Miami📍 Boston📍 Boston Jennifer Crombie, MD · Tests: Glofitamab, Polatuzumab, Rituximab, Doxorubicin Hydrochloride, Cyclophosphamide A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. NCT06022029Phase 116 sites📍 Los Angeles📍 Tamarac📍 Canton OncoNano Medicine, Inc. · Tests: ONM-501, Cemiplimab Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma NCT06854445Phase 224 sites📍 Wuhu📍 Xiamen📍 Lanzhou Shanghai Chia Tai Tianqing Pharmaceutical Technology Develo… · Tests: TQB2825 Injection + Gemcitabine Hydrochloride for Injection + Oxaliplatin for Injection Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T NCT06784726Phase 21 site📍 Seattle University of Washington · Tests: Odronextamab, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Chimeric Antigen Receptor T-Cell Ther… Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma NCT07078500Phase 21 site📍 Hangzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: orelabrutinib combined with the Pola-R-CHP regimen Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL NCT06832267NA1 site📍 Hangzhou Zhejiang Cancer Hospital · Tests: Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT)
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy